p24 antigen screening to reduce the risk of HIV transmission by seronegative bone allograft donors.
BACKGROUND
During the last decade, more than 2000 bone allografts harvested from 888 donors and processed by the Queensland Bone Bank have been transplanted in over 1500 patients in Australia and New Zealand. A strict protocol to eliminate HIV transmission by fresh frozen allografts is followed; and not a single case of HIV transmission has been reported.


METHODS
All donors were screened and strict donor exclusion criteria were used. All donor blood samples were subjected to double testing including antibody to HIV-1, HIV-2 and HTLV-1 and p24 antigen. The allografts negative for these tests were subjected to processing, including removal of extraneous tissue, pulsatile lavage to remove marrow elements, and immersion in 97% alcohol for 20 minutes. Allografts were subjected to 25 cGy irradiation before transplantation.


RESULTS
Allografts were retrieved from a total of 950 donors and 51 were discarded after screening for contamination by organisms other than HIV-1. Eleven donors negative for HIV-1 antibodies tested positive for p24 antigen and were discarded. Allografts from donors testing negative for both the tests (n = 888) were irradiated and used for transplantation.


CONCLUSIONS
Routine p24 antigen testing and irradiation of allograft should be mandatory for bone banks, especially those freezing fresh allografts. p24 antigen testing is inexpensive, rapid and easy. Certain guidelines must be followed to avoid misleading results of p24 testing.
Malhotra
R
R
All India Institute of Medical Sciences, New Delhi, India.
Morgan
D A
DA
D016025:Bone Transplantation / Q000009:adverse effects*; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D016655:HIV Core Protein p24 / Q000276:immunology*; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission*; D015497:HIV-1 / Q000276:immunology; D015498:HIV-2 / Q000276:immunology; D015481:HTLV-I Antibodies / Q000097:blood*; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D012307:Risk Factors; D014184:Transplantation, Homologous / Q000009:adverse effects
D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015481:HTLV-I Antibodies